Blood test may personalize chemo for aggressive colon cancer
NCT ID NCT07562490
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with high-risk stage III colorectal cancer. It tests whether using a blood test (ctDNA) to guide treatment decisions can improve outcomes. Participants will receive either standard chemotherapy or chemotherapy plus bevacizumab, with regular blood monitoring. The goal is to see if the added drug helps prevent cancer from returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?